BNP Paribas Arbitrage SA grew its stake in shares of Sientra Inc (NASDAQ:SIEN) by 97,300.0% in the first quarter, HoldingsChannel.com reports. The fund owned 4,870 shares of the medical instruments supplier’s stock after purchasing an additional 4,865 shares during the period. BNP Paribas Arbitrage SA’s holdings in Sientra were worth $42,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its holdings in shares of Sientra by 1.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 221,093 shares of the medical instruments supplier’s stock valued at $5,280,000 after acquiring an additional 2,726 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Sientra by 6.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 163,888 shares of the medical instruments supplier’s stock valued at $3,913,000 after acquiring an additional 9,245 shares during the period. Vanguard Group Inc. increased its holdings in shares of Sientra by 1.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,017,312 shares of the medical instruments supplier’s stock valued at $24,293,000 after acquiring an additional 14,422 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Sientra in the 4th quarter valued at $29,000. Finally, Rhumbline Advisers increased its holdings in shares of Sientra by 50.6% in the 4th quarter. Rhumbline Advisers now owns 30,301 shares of the medical instruments supplier’s stock valued at $385,000 after acquiring an additional 10,180 shares during the period. Institutional investors own 86.05% of the company’s stock.

Shares of SIEN stock opened at $6.03 on Wednesday. Sientra Inc has a 1-year low of $5.00 and a 1-year high of $26.79. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.58. The firm has a market cap of $176.20 million, a P/E ratio of -1.86 and a beta of 0.27.

Sientra (NASDAQ:SIEN) last announced its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.15). Sientra had a negative return on equity of 119.59% and a negative net margin of 126.32%. The business had revenue of $17.55 million for the quarter, compared to analysts’ expectations of $17.00 million. On average, equities research analysts forecast that Sientra Inc will post -2.9 earnings per share for the current fiscal year.

Several research analysts recently weighed in on SIEN shares. BidaskClub upgraded Sientra from a “strong sell” rating to a “sell” rating in a research note on Friday, March 1st. William Blair downgraded Sientra from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 13th. ValuEngine upgraded Sientra from a “hold” rating to a “buy” rating in a research note on Thursday, February 28th. Craig Hallum set a $23.00 target price on Sientra and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Finally, Leerink Swann dropped their target price on Sientra from $22.00 to $18.00 in a research note on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.13.

In other Sientra news, CFO Paul Sean Little bought 17,391 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were purchased at an average cost of $5.75 per share, for a total transaction of $99,998.25. Following the purchase, the chief financial officer now directly owns 94,891 shares in the company, valued at $545,623.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Keith J. Sullivan purchased 20,869 shares of the company’s stock in a transaction on Friday, June 7th. The shares were purchased at an average price of $5.75 per share, for a total transaction of $119,996.75. Following the purchase, the director now owns 203,141 shares in the company, valued at approximately $1,168,060.75. The disclosure for this purchase can be found here. 31.00% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “BNP Paribas Arbitrage SA Boosts Stake in Sientra Inc (NASDAQ:SIEN)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.watchlistnews.com/bnp-paribas-arbitrage-sa-boosts-stake-in-sientra-inc-nasdaqsien/3038985.html.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: The risks of owning bonds

Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).

Institutional Ownership by Quarter for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.